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OBJECTIVES: Assess the clinimetric properties of the
MIGRAINE-SCREEN-Q (MS-Q) questionnaire for the screen-
ing of patients with migraine in the general population.
METHODS: A 16-item tool was developed from the Interna-
tional Headache Criteria (IHS) of Migraine and a review of the
literature by a panel of 6 experts in neurology, occupational med-
icine, clinimetrics, and methodology. The MS-Q instrument was
mailed and ﬁlled in by the employees working for at least 3
months at the Pﬁzer company (Step I) and self-administered to
patients of a Neurological Clinic (Step II and III) in Spain. All
subjects were subsequently referred for an independent diagno-
sis by a neurologist, blinded of MS-Q results. The diagnosis was
assigned according to IHS criteria. Statistical methods included
logistic regression, ROC curves analysis and determination of
sensitivity, speciﬁcity, and positive and negative predictive values
with its 95% conﬁdence interval. RESULTS: In all, 415 employ-
ees (Step I) and 50 patients (Step II) were recruited. Of them,
325 subjects were evaluable and diagnosed as having migraine
(n = 85), other headaches (n = 80) and non-headache subjects (n
= 160). A further 140 patients were recruited in a Neurological
Clinic and analysed independently to get a sample of 70 migraine
and 70 non-migraine patients (Step III). A ﬁve-item subset
(headache frequency and severity, 4 hours’ to 3 days’ duration,
nausea, sensitivity to light/noise and disability) out of 16 pre-
liminary items was derived by logistic regression analyses. A cut-
off of 4 or more points provided a sensitivity of 0.93 (95%CI,
0.87–0.99), speciﬁcity of 0.81 (0.72–0.91), a positive predictive
value of 0.83 (0.75–0.91) and a negative predictive value of 0.92
(0.85–0.99). The reliability Cronbach Alpha coefﬁcient was
0.82. CONCLUSIONS: The 5-item MIGRAINE SCREEN-Q
instrument was found to be a valid and reliable screening tool
for migraine headaches. Further studies are warranted to test its
applicability in the general population.
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OBJECTIVE: IRLS is used for clinical assessment and severity
of Restless Legs Syndrome (RLS). To compare the burden of RLS
with other health states, this study has mapped the IRLS to a
multi-attribute utility measure, the EQ-5D. METHODS: Four
RLS experts from Spain, France, UK and US were identiﬁed to
participate in mapping the ten IRLS items (each with ﬁve ordinal
response levels) to the ﬁve EQ-5D domains (each with three
ordinal response levels). A pilot study conducted by one expert
identiﬁed two issues: 1) the disease characteristics of RLS and
the 10 IRLS items could not be mapped to EQ-5D domains of
“Self-care” and “Mobility” (EQ-5D level “1” was assigned to
both), and 2) IRLS question three (relating to relief from move-
ment) proved difﬁcult to map; an algorithm to map this was
developed. All experts then completed their individual mapping
responses. Discrepancies were resolved through consensus result-
ing in one ﬁnal mapping response. RESULTS: The experts con-
cluded that the EQ-5D domains of “Pain/Discomfort”, “Usual
Activities” and “Anxiety/Depression” were appropriate for
mapping to the 10 IRLS items (each item mapped once).
“Pain/Discomfort” mapped to four IRLS items, “Usual Activi-
ties” mapped to ﬁve IRLS items and “Anxiety/Depression”
mapped to one IRLS item. Ordinal responses for each IRLS item
were mapped to appropriate ordinal responses on the three EQ-
5D domains. EQ-5D utilities could be established for different
combinations of IRLS item responses and corresponding IRLS
total scores. Using trial data, a signiﬁcant correlation between
IRLS total scores and EQ-5D utilities was established (r = -0.84,
p < 0.0001). CONCLUSION: Based on clinical consensus, the
IRLS can be successfully mapped to the EQ-5D. The algorithm
resulting from this work may be used to compare health related
QoL of RLS sufferers with those of other diseases for resource
allocation decisions.
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OBJECTIVES: The development of Markov decision models for
chronic diseases is often time-consuming and sophisticated.
Therefore, generic and ﬂexible models have advantages. We
present a method that allows to externally adjust decision models
for context-speciﬁc variables such as epidemiologic, clinical, or
economic parameters. METHODS: To allow transfer of decision
models across populations or countries with correct adjustment
for context-speciﬁc parameters, we used centered regression
equations instead of ﬁxed values as model parameters. Clinical
event probabilities, utilities, and costs were deﬁned as functions
of context-speciﬁc predictors. Centering the predictors on their
means allows to interpret intercepts as grand means and regres-
sion coefﬁcients as relative modiﬁers. We applied this approach
to the Parkinson’s Disease Model (PDM) using 1-year follow-up
data of target outcomes (clinical events, utilities [EQ-5D], and
costs) from the German Parkinson’s Disease Competence
Network Study (n = 145). We validated the centered regression
approach by comparing model results to those from models with
model parameters based on non-centered regression and ﬁxed
parameters values. RESULTS: Target outcomes of PDM were
deﬁned by 1) centered regression equations; 2) intercepts repre-
senting grand means of 1-year target outcomes (anchor value);
3) distribution of disease severity stages; and 4) regression coef-
ﬁcients for each stage representing additive (utilities) or multi-
plicative (events, costs) modiﬁers for the anchor value. Assuming
constant modiﬁers, the model can be transferred if data on mean
outcomes and severity stage distribution of the target country are
available. Sensitivity analyses were facilitated, as changes in
overall event risk, utilities, or costs were achieved by simply
changing intercepts. Validation of the centered regression-based
PDM with non-centered regression equations or using ﬁxed
values in the model led to identical results. CONCLUSIONS:
The implementation of centered regression-based equations in a
decision model enhances model ﬂexibility with respect to sensi-
tivity analyses and transferability to another population or
health care context.
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OBJECTIVES: Estimating the cost of a disease for Europe is a
methodological challenge due to differences in epidemiology,
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treatment patterns, prices and data availability. This study aims
at developing a model to overcome these challenges and to
combine epidemiology and economic data to estimate the cost
of MS in Europe. METHODS: A model was developed, based
on the prevalence of the disease and the cost per patient for dif-
ferent degrees of severity of disease, with the following purposes:
1) transform and convert available economic data to a deﬁned
time period as well as currency; 2) adjust country speciﬁc eco-
nomic data for purchasing power and relative size of economy;
3) impute data for countries where no data are available; and 4)
combine epidemiology and economic data to estimate the total
cost of a deﬁned disease. The model was populated with Euro-
pean published data on multiple sclerosis. National and inter-
national statistics for the model were retrieved from the OECD
and Eurostat databases. The estimates were presented in Euro
for 2003. RESULTS: The estimated cost for MS in Europe is
10.7€ billion. Mild patients with MS accounted for 53% of the
total cost, moderate 25% and severe patients for 22%. The high
income countries accounted for 77% of the total cost and the
countries with high prevalence in MS constituted 80% of the
total cost. The model estimates for drug costs were validated
against other data on total costs for MS drugs in Europe. CON-
CLUSIONS: The model provides a novel approach to estimat-
ing the cost of illness of a disease in Europe, as illustrated with
the example of MS.
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OBJECTIVES: The lack of epidemiological data has suggested
to perform an Italian retrospective study with the objective to
assess the health resources consumption that are caused by
acromegalic cure and the relative co-morbidities in order to esti-
mate the amount of the direct cost of acromegalic patients.
METHODS: A retrospective study has been performed on a total
of 134 patients (142 patients selected, 76 patients by site of
Genoa and 66 patients by the site of Turin) for a period of about
7 years preceding the enrolment date. For the observation study
period all hospitalizations (ordinary hospitalization and Day-
Hospital), all specialist visits and diagnostic and laboratory tests
have been collected, for each patient, from the relative medical
records independently if the health care resources used were due
to the primary disease or to co-morbidities. Only direct costs
have been evaluated by performing an analysis on the perspec-
tive of Italian Healthcare Service (SSN). RESULTS: The mean
total direct costs for acromegaly cure ranged from 8,526 to
12,546€ €/year (p = 0.008, Mann Whitney Test), respectively, for
controlled and not controlled patients. Pointing out that the cost
driver was represented by drug (somatostatin analogs) for
acromegalic cure, the not controlled patient group showed a
major use of drugs and the relative mean annual cost was about
1.66 times than that of controlled patient group (mean annual
drug cost 6,438€ ± 8993 in the controlled group vs 10,719€ ±
10,012 in not-controlled group; p = 0.012). CONCLUSION:
The study support the hypothesis that controlled patients drove
a saving for SSN in comparison to poor control patients that use
more health resources.
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OBJECTIVES: To quantify the differences in health-related
quality of life within and between adults with GHD and the
general population in Spain and England & Wales (E&W),
respectively, using the disease-speciﬁc instrument QoL—Assess-
ment of Growth Hormone Deﬁciency in Adults (QoL-AGHDA).
METHODS: QoL-AGHDA is a 25-item questionnaire that
elicits yes/no responses to personal statements describing prob-
lems that characterize aspects of HrQoL in growth hormone deﬁ-
ciency. A high QoL-AGHDA score denotes poor HrQoL. The
Spanish population sample comprised 940 individuals, and the
England and Wales sample 921. These survey data were collected
in studies reported elsewhere (Badia and Koltowska–Häggström,
respectively). Patient data were retrieved from KIMS (Pﬁzer
International Metabolic Database). The number of patients from
the two countries were 315 and 836, respectively. Student t-tests
were performed on mean data for groups formed by 10-year age
bands and gender. RESULTS: For Spain the mean QoL-AGHDA
was 11.0 for patients and 5.1 in the general population. For
E&W the corresponding means were 14.7 and 6.7. The mean
deﬁcits for patients compared with the general population were
similar in all age- and gender groups and were statistically sig-
niﬁcant (p < 0.0001). The mean patient QoL-AGHDA from
E&W were signiﬁcantly higher in most age and gender categories
compared with the Spanish patients (p < 0.05). The general pop-
ulation QoL-AGHDA scores in men did not differ signiﬁcantly
between countries (Spain = 5.9 vs. E&W = 6.2), but women from
Spain scored signiﬁcantly lower (higher HrQoL) than women
from E&W (3.9 vs. 7.0; p < 0.0001). CONCLUSIONS: This
study conﬁrms the extent of deﬁcit in HrQoL in adults with
GHD compared to general population. For patient comparisons,
caution is needed in interpreting these results, since the eligibil-
ity criteria for GH replacement differ between the two countries.
The reasons for gender variability between Spain and E&W
general population requires further studies.
URINARY/KIDNEY DISEASES DISORDERS
URINARY/KIDNEY DISEASES DISORDERS—Cost Studies
PUK1
THE COST-EFFECTIVENESS OF EXTENDED RELEASE
TOLTERODINE IN THE MANAGEMENT OF OVERACTIVE
BLADDER IN GERMANY AND THE UNITED KINGDOM
Anderson P1, Resch A2, Dooley JA3, Brüggenjürgen B4, Zlateva G5
1Fourth Hurdle Consulting Ltd, London, UK; 2Pﬁzer GmBH, Karlsruhe,
Germany; 3Pﬁzer Ltd,Tadworth, UK; 4Alpha Care GmbH, Celle,
Germany; 5Pﬁzer, Inc, New York, NY, USA
OBJECTIVE: Adequate treatment of patients with overactive
bladder (OAB) depends signiﬁcantly on the rate of persistence
